vs

Side-by-side financial comparison of INTEST CORP (INTT) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

INTEST CORP is the larger business by last-quarter revenue ($32.8M vs $20.6M, roughly 1.6× Pulmonx Corp). INTEST CORP runs the higher net margin — 3.8% vs -66.3%, a 70.1% gap on every dollar of revenue. On growth, Pulmonx Corp posted the faster year-over-year revenue change (-8.7% vs -10.3%). Over the past eight quarters, INTEST CORP's revenue compounded faster (4.9% CAGR vs -0.5%).

INTTEST Corp designs, manufactures and distributes precision test and process control solutions for the global semiconductor manufacturing ecosystem. Its offerings include thermal management systems, test interface hardware, and wafer handling tools, serving semiconductor fabs, chip design firms, and automotive and industrial electronics end segments.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

INTT vs LUNG — Head-to-Head

Bigger by revenue
INTT
INTT
1.6× larger
INTT
$32.8M
$20.6M
LUNG
Growing faster (revenue YoY)
LUNG
LUNG
+1.7% gap
LUNG
-8.7%
-10.3%
INTT
Higher net margin
INTT
INTT
70.1% more per $
INTT
3.8%
-66.3%
LUNG
Faster 2-yr revenue CAGR
INTT
INTT
Annualised
INTT
4.9%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
INTT
INTT
LUNG
LUNG
Revenue
$32.8M
$20.6M
Net Profit
$1.2M
$-13.7M
Gross Margin
45.4%
77.9%
Operating Margin
3.9%
-40.9%
Net Margin
3.8%
-66.3%
Revenue YoY
-10.3%
-8.7%
Net Profit YoY
-17.4%
5.5%
EPS (diluted)
$0.10
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INTT
INTT
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$32.8M
$22.6M
Q3 25
$26.2M
$21.5M
Q2 25
$28.1M
$23.9M
Q1 25
$26.6M
$22.5M
Q4 24
$36.6M
$23.8M
Q3 24
$30.3M
$20.4M
Q2 24
$34.0M
$20.8M
Net Profit
INTT
INTT
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$1.2M
$-10.4M
Q3 25
$-938.0K
$-14.0M
Q2 25
$-503.0K
$-15.2M
Q1 25
$-2.3M
$-14.4M
Q4 24
$1.5M
$-13.2M
Q3 24
$495.0K
$-14.1M
Q2 24
$230.0K
$-15.3M
Gross Margin
INTT
INTT
LUNG
LUNG
Q1 26
77.9%
Q4 25
45.4%
77.6%
Q3 25
41.9%
74.7%
Q2 25
42.6%
72.1%
Q1 25
41.5%
72.5%
Q4 24
39.7%
74.0%
Q3 24
46.3%
73.7%
Q2 24
40.6%
73.7%
Operating Margin
INTT
INTT
LUNG
LUNG
Q1 26
-40.9%
Q4 25
3.9%
-43.8%
Q3 25
-4.5%
-66.9%
Q2 25
-3.3%
-62.0%
Q1 25
-10.8%
-64.6%
Q4 24
5.7%
-56.5%
Q3 24
1.6%
-69.3%
Q2 24
1.0%
-75.2%
Net Margin
INTT
INTT
LUNG
LUNG
Q1 26
-66.3%
Q4 25
3.8%
-46.1%
Q3 25
-3.6%
-64.9%
Q2 25
-1.8%
-63.6%
Q1 25
-8.7%
-64.1%
Q4 24
4.1%
-55.4%
Q3 24
1.6%
-69.4%
Q2 24
0.7%
-73.7%
EPS (diluted)
INTT
INTT
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$0.10
$-0.25
Q3 25
$-0.08
$-0.34
Q2 25
$-0.04
$-0.38
Q1 25
$-0.19
$-0.36
Q4 24
$0.13
$-0.33
Q3 24
$0.04
$-0.36
Q2 24
$0.02
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INTT
INTT
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$14.2M
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$103.6M
$45.8M
Total Assets
$151.3M
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INTT
INTT
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$14.2M
$69.8M
Q3 25
$16.2M
$76.5M
Q2 25
$19.2M
$75.5M
Q1 25
$22.0M
$74.6M
Q4 24
$19.8M
$70.9M
Q3 24
$18.0M
$63.3M
Q2 24
$20.4M
$63.5M
Total Debt
INTT
INTT
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$4.9M
$37.1M
Q2 25
$5.9M
$37.1M
Q1 25
$6.9M
$37.2M
Q4 24
$7.9M
$37.2M
Q3 24
$9.0M
$37.2M
Q2 24
$10.0M
$37.2M
Stockholders' Equity
INTT
INTT
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$103.6M
$54.1M
Q3 25
$101.9M
$60.0M
Q2 25
$102.6M
$69.1M
Q1 25
$99.4M
$77.7M
Q4 24
$99.8M
$85.8M
Q3 24
$100.4M
$93.9M
Q2 24
$99.5M
$101.2M
Total Assets
INTT
INTT
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$151.3M
$129.3M
Q3 25
$148.3M
$138.3M
Q2 25
$149.7M
$147.2M
Q1 25
$148.0M
$150.7M
Q4 24
$152.3M
$162.8M
Q3 24
$158.4M
$167.4M
Q2 24
$160.6M
$172.6M
Debt / Equity
INTT
INTT
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.05×
0.62×
Q2 25
0.06×
0.54×
Q1 25
0.07×
0.48×
Q4 24
0.08×
0.43×
Q3 24
0.09×
0.40×
Q2 24
0.10×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INTT
INTT
LUNG
LUNG
Operating Cash FlowLast quarter
$-1.0M
Free Cash FlowOCF − Capex
$-1.6M
FCF MarginFCF / Revenue
-4.7%
Capex IntensityCapex / Revenue
1.6%
Cash ConversionOCF / Net Profit
-0.82×
TTM Free Cash FlowTrailing 4 quarters
$5.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INTT
INTT
LUNG
LUNG
Q1 26
Q4 25
$-1.0M
$-7.1M
Q3 25
$3.5M
$-8.2M
Q2 25
$-688.0K
$-3.9M
Q1 25
$5.5M
$-13.2M
Q4 24
$2.6M
$-6.7M
Q3 24
$4.2M
$-7.2M
Q2 24
$-5.1M
$-5.8M
Free Cash Flow
INTT
INTT
LUNG
LUNG
Q1 26
Q4 25
$-1.6M
$-7.1M
Q3 25
$3.1M
$-8.3M
Q2 25
$-1.1M
$-4.0M
Q1 25
$5.3M
$-13.5M
Q4 24
$2.4M
$-6.8M
Q3 24
$3.7M
$-7.7M
Q2 24
$-5.4M
$-6.2M
FCF Margin
INTT
INTT
LUNG
LUNG
Q1 26
Q4 25
-4.7%
-31.4%
Q3 25
11.8%
-38.4%
Q2 25
-4.1%
-16.6%
Q1 25
19.9%
-60.0%
Q4 24
6.6%
-28.8%
Q3 24
12.4%
-37.6%
Q2 24
-15.9%
-30.0%
Capex Intensity
INTT
INTT
LUNG
LUNG
Q1 26
Q4 25
1.6%
0.1%
Q3 25
1.6%
0.4%
Q2 25
1.6%
0.2%
Q1 25
0.9%
1.3%
Q4 24
0.4%
0.5%
Q3 24
1.7%
2.0%
Q2 24
0.9%
2.3%
Cash Conversion
INTT
INTT
LUNG
LUNG
Q1 26
Q4 25
-0.82×
Q3 25
Q2 25
Q1 25
Q4 24
1.72×
Q3 24
8.58×
Q2 24
-22.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INTT
INTT

Environmental Technologies$8.3M25%
Semiconductor Market$6.9M21%
Thermal Testing Products$6.4M19%
Service And Other Products$4.8M15%
Oem Integrators And Distributor$3.5M11%
Semiconductor Production Test Products$3.0M9%

LUNG
LUNG

Segment breakdown not available.

Related Comparisons